A multidisciplinary expert consensus in Menopause examined evidence on MHT in women with a history of breast cancer.
What the Research Shows
Gynecologists, oncologists, and menopause specialists synthesized research on systemic and local estrogen use after breast cancer.
Key conclusions:
• Evidence remains limited with no large randomized trials on MHT safety after breast cancer.
• Panel supports shared decision-making, balancing symptom burden against recurrence risk.
• Individual risk profiles should guide care; MHT may be off-label when benefit outweighs risk.
• Formal trial enrollment (e.g., MENO-ABC trial) needed for high-quality data.
• Panel supports shared decision-making, balancing symptom burden against recurrence risk.
• Individual risk profiles should guide care; MHT may be off-label when benefit outweighs risk.
• Formal trial enrollment (e.g., MENO-ABC trial) needed for high-quality data.
What This Means for Clinical Care
Individualized, patient-centered menopause care is essential for breast cancer survivors.
• Evidence gaps require careful risk-benefit discussions.
• Symptom burden and quality of life are valid considerations.
• Both systemic and local estrogen options should be discussed.
• Symptom burden and quality of life are valid considerations.
• Both systemic and local estrogen options should be discussed.
Balancing Risk and Quality of Life
Until more robust data emerges, clinicians should engage in thorough shared decision-making with breast cancer survivors experiencing menopause symptoms, weighing the potential benefits of MHT against individual recurrence risk.
Get provider-only pricing, ready-to-share patient resources, and clinical training – whatever your specialty.
Become and Intimate Rose Partner
